DEFLORIAN, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 890
EU - Europa 177
AS - Asia 161
SA - Sud America 9
OC - Oceania 1
Totale 1.238
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 875
VN - Vietnam 74
CN - Cina 63
DE - Germania 46
FI - Finlandia 20
SE - Svezia 19
FR - Francia 18
IT - Italia 17
UA - Ucraina 15
CA - Canada 14
IE - Irlanda 13
SG - Singapore 13
GR - Grecia 12
GB - Regno Unito 9
TR - Turchia 9
BR - Brasile 8
BG - Bulgaria 3
RO - Romania 2
BZ - Belize 1
CL - Cile 1
ES - Italia 1
IN - India 1
JP - Giappone 1
NZ - Nuova Zelanda 1
RU - Federazione Russa 1
SI - Slovenia 1
Totale 1.238
Salva come PNG Salva come JPEG
Città #
Fairfield 188
Woodbridge 78
Dong Ket 74
Cambridge 71
Chandler 69
Wilmington 61
Ashburn 58
Seattle 57
Houston 54
Jacksonville 54
Princeton 29
Ann Arbor 25
Columbus 20
Dublin 13
Beijing 12
Des Moines 11
San Diego 11
Singapore 9
Yenibosna 9
Helsinki 8
North York 8
Nanjing 6
Americana 5
Jinan 5
Munich 5
Kharkiv 4
Nanchang 4
Tianjin 4
Treviso 4
London 3
Medford 3
Montréal 3
Ningbo 3
Padova 3
Philadelphia 3
Shenyang 3
Sofia 3
São Paulo 3
Boardman 2
Changsha 2
Council Bluffs 2
Hangzhou 2
Hebei 2
Indiana 2
Marseille 2
Montreal 2
New York 2
Rockville 2
San Jose 2
Taizhou 2
Telgate 2
Belize City 1
Berlin 1
Bologna 1
Brookline 1
Cartagena 1
Falls Church 1
Frankfurt am Main 1
Guangzhou 1
Horia 1
Hounslow 1
Jiaxing 1
Kilburn 1
Las Vegas 1
Los Angeles 1
Mcallen 1
Milan 1
Milwaukee 1
Norwalk 1
Ogden 1
Pinehaven 1
Portland 1
Prescot 1
Pune 1
Qingdao 1
Redwood City 1
Rome 1
Roxbury 1
Saint Louis 1
Tappahannock 1
Timisoara 1
Tokyo 1
Toronto 1
Trieste 1
Verona 1
Yellow Springs 1
Zhengzhou 1
Totale 1.045
Salva come PNG Salva come JPEG
Nome #
1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies. 285
Combining ligand-based and structure-based drug design in the virtual screening arena 114
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: a complete structure -activity profile. 104
Tandem 3D-QSARs approach as a valuable tool to predict binding affinity data: Design of new Gly/NMDA receptor antagonists as a key study 95
G protein-coupled receptors as challenging druggable targets: insights from in silico studies 94
Demystifying the three dimensional structure of G protein- coupled receptors (GPCRs) with the aid of molecular modeling 90
Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Synthesis, pharmacological, and molecular modeling studies 86
Novel strategies for the design of new potent and selective human A3 receptor antagonists: an update 79
Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity 77
Application of a molybdenum and tungsten disulfide coating to improve tribological properties of orthodontic archwires 76
Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists: influence of the N5 substituent on the affinity at the human A3 and A2B adenosine receptor subtypes. 55
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A(3) and A(2B) adenosine receptor subtypes: A molecular modeling investigation 52
Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A(3) adenosine receptor antagonists: Pyrazolo[4,3-e]1,2,4- triazolo[1,5-c]pyrimidine derivatives as a key study 38
Totale 1.245
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.126
article - articoli 4.126
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.252
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020217 0 5 12 17 24 35 22 26 34 20 15 7
2020/2021270 16 6 8 20 6 35 0 10 35 20 34 80
2021/2022205 16 23 20 15 1 15 14 25 7 9 19 41
2022/2023166 32 15 2 19 20 41 0 10 15 2 7 3
2023/2024102 3 11 25 3 16 4 19 5 2 1 6 7
Totale 1.245